ANGLE plc (GB:AGL) has released an update.
ANGLE plc has strategically refocused its business to prioritize services for large pharmaceutical companies, resulting in the successful acquisition of three significant contracts with substantial revenue potential. Despite a downturn in product sales due to regulatory changes and a global research funding slowdown, the company has managed to reduce its half-year losses by 21% and is in a strong cash position after a recent fundraise. The company is optimistic about future growth, with new pharma contracts and advancements in their proprietary Parsortix technology for cancer drug trials.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.